atrasentan has been researched along with Hypertension, Portal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, HQ; Rockey, DC; Weymouth, ND | 1 |
| De Gottardi, A; Reichen, J; Sägesser, H; Shaw, S | 1 |
2 other study(ies) available for atrasentan and Hypertension, Portal
| Article | Year |
|---|---|
Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease.
Topics: Animals; Atrasentan; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelins; Hypertension, Portal; Infusions, Intravenous; Liver; Liver Circulation; Liver Cirrhosis, Experimental; Male; Mice; Mice, Inbred C57BL; Portal Pressure; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Time Factors; Vasoconstriction; Vasodilation | 2009 |
Type A, but not type B, endothelin receptor antagonists significantly decrease portal pressure in portal hypertensive rats.
Topics: Animals; Atrasentan; Endothelin Receptor Antagonists; Endothelin-1; Hypertension, Portal; Male; Portal Pressure; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B | 2000 |